NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (Japon)
TOKYO WOMEN'S MEDICAL UNIVERSITY (Japon)
Inventeur(s)
Hasunuma, Tomohisa
Kato, Yuichi
Inabe, Kosuke
Kondo, Akihiko
Shimizu, Tatsuya
Haraguchi, Yuji
Abrégé
According to the present disclosure, there is provided a system for culturing animal cells using a component derived from an organism such as algae as a nutrient source, and reusing the culture waste liquid. The present disclosure provides an organism or a cultured cell which undergoes a modification, in which the modification includes imparting or enhancing L-lactate utilization ability in the organism or the cultured cell. In addition, the present disclosure provides a method for culturing at least two types of cells including a cell X and a cell Y in a circulation manner, the method including: a step (a) of providing a component excreted from the cell X to the cell Y; a step (b) of providing a component derived from the cell Y to the cell X; a step (c) of culturing the cell X and the cell Y; and a step (d) of repeating the steps (a) to (c) as necessary, in which at least one of the components excreted from the cell X is an assimilable component of the cell Y, and at least one of the components derived from the cell Y is a nutritional component of the cell X.
C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
C12N 1/12 - Algues unicellulairesLeurs milieux de culture
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
An immunoisolation device that reduces diffusion distance, which is effective for increasing the permeability of substances such as physiologically active substances and nutrients, and has improved durability to withstand long-term transplantation. The immunoisolation device includes a sheet-like cell aggregate containing cells and an extracellular matrix, and an immunoisolation layer that covers the cell aggregate.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
The present invention provides an algae culturing method in which a composition containing a medium that has been used to culture animal cells is used as a medium. The present invention further provides a composition for culturing algae, the composition containing a medium that has been used to culture animal cells. Moreover, the present invention provides an algae and animal cell recycle culturing method.
C12N 1/12 - Algues unicellulairesLeurs milieux de culture
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
4.
METHOD FOR PRODUCING COMPOSITION FOR CULTURING ANIMAL CELLS, COMPOSITION FOR CULTURING ANIMAL CELLS OBTAINED BY SAID METHOD, AND METHOD FOR CULTURING ANIMAL CELLS USING SAID COMPOSITION FOR CULTURING ANIMAL CELLS
The present invention provides a method for producing a composition for culturing animal cells, wherein the method includes: (1) a step in which an algae is mixed with a solid acid catalyst and an algae extract is obtained by heating; and (2) a step in which the algae extract is added to a medium for culturing animal cells and the concentration of the algae extract is adjusted. The present invention also provides a recycling/culturing method for algae and animal cells including: (i) a step in which a waste liquid (a first waste liquid) previously used to culture animal cells is used to culture algae; (ii) a step in which the algae is collected, mixed with a solid catalyst, and heated, and an algae extract is thereby obtained; (iii) a step in which the algae extract is added to the waste liquid (a second waste liquid) previously used to culture algae in (i), the concentration of the algae extract is adjusted, and a composition for culturing animal cells is produced; and (iv) a step in which animal cells are cultured using the composition for culturing animal cells.
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 1/12 - Algues unicellulairesLeurs milieux de culture
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
5.
CULTURE SUBSTRATE, METHOD FOR PRODUCING CULTURE SUBSTRATE, METHOD FOR PRODUCING CELL, AND REUSABLE CULTURE SUBSTRATE
Provided is a culture substrate which comprises, on a metal substrate that has undergone oxygen plasma processing and silanization processing, a temperature-responsive polymer having a glass transition temperature of greater than 121°C.
A plasma exchanging system 100 is provided with: an oxygenator 20 that adds oxygen to a liquid for adding oxygen to blood; a plasma separator 10 having a hollow fiber membrane through which plasma migration from blood to the liquid, oxygen migration from the liquid to blood, and carbon dioxide migration from blood to the liquid occur; and a fractionator 30 that fractionates plasma included in the liquid.
[Problem] The purpose is to provide a novel method for culturing myoblasts or skeletal muscle stem cells. [Solution] The method for culturing myoblasts or skeletal muscle stem cells of the present invention includes a step that cultures myoblasts or skeletal muscle stem cells in a medium containing the culture supernatant of epithelial cells.
The problem to be solved by the present invention is to provide: an immunoisolation device which can achieve both of the reduction in diffusion distance effective for the improvement in permeability of a substance such as a physiologically active substance and a nutrient and the improvement in durability for withstanding transplantation for a long period of time; and an immunological control technology using a cell sheet. The present invention provides an immunoisolation device provided with a sheet-like cell mass containing cells and an extracellular matrix and an immunoisolation layer that covers the cell mass.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
S100A8-inhibiting peptides include (A) a peptide of 5 to 10 residues in length containing a fifth alanine (Ala) from an N-terminus in an amino acid sequence of SEQ ID NO: 1, or (B) a peptide consisting of an amino acid sequence of SEQ ID NO: 2.
A drill stopper (1) comprises: a body (2) having a through-hole (2a) through which a drill shaft penetrates; and a lever (3) supported by the body (2) such that the lever (3) can rotate about a predetermined rotation axis between a fixation position at which the body (2) is fixed to the drill shaft inside the through-hole (2a) and a fixation releasing position at which the body (2) is released from the drill shaft. The lever (3) has an abutting part (3c) abutting, in the direction along the central axis (O) of the through-hole (2a), against another member attached to the drill shaft. The abutting part (3c) is disposed at a position apart, in the direction along the central axis (O), from the body (2) in the state where the lever (3) is placed at the fixation releasing position.
NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (Japon)
TOKYO WOMEN'S MEDICAL UNIVERSITY (Japon)
Inventeur(s)
Hasunuma, Tomohisa
Kato, Yuichi
Inabe, Kosuke
Kondo, Akihiko
Shimizu, Tatsuya
Haraguchi, Yuji
Abrégé
The present disclosure provides a system for culturing animal cells by using, as a source of nutrient, components derived from a living organism such as algae, and for reutilizing a waste culture liquid obtained therefrom. The present disclosure provides a living organism or a cultured cell, which has undergone a modification. Said modification includes providing or enhancing the ability to utilize L-lactic acid in the living organism or the cultured cell. The present disclosure also provides a method for culturing, in recycling-oriented manner, at least two types of cells, which are cell X and cell Y, the method comprising: a step (a) for providing components excreted from the cell X to the cell Y; a step (b) for providing components originating from the cell Y to the cell X; a step (c) for culturing the cell X and the cell Y; and, as necessary, a step (d) for repeating steps (a)-(c). At least one of the components excreted from the cell X is a component that can be utilized by the cell Y. At least one of the components originating from the cell Y is a nutritional component for the cell X.
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 1/12 - Algues unicellulairesLeurs milieux de culture
C12N 1/13 - Algues unicellulairesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/31 - Gènes codant pour des protéines microbiennes, p. ex. entérotoxines
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A23L 13/00 - Produits à base de viandeFarine de viandeLeur préparation et leur traitement
12.
METHOD FOR PRODUCING COMPOSITION FOR CULTURING ANIMAL CELLS, COMPOSITION FOR CULTURING ANIMAL CELLS OBTAINED BY SAID METHOD, AND METHOD FOR CULTURING ANIMAL CELLS USING SAID COMPOSITION FOR CULTURING ANIMAL CELLS
The present invention provides a method for producing a composition for culturing animal cells, wherein the method includes: (1) a step in which an algae is mixed with a solid acid catalyst and an algae extract is obtained by heating; and (2) a step in which the algae extract is added to a medium for culturing animal cells and the concentration of the algae extract is adjusted. The present invention also provides a recycling/culturing method for algae and animal cells including: (i) a step in which a waste liquid (a first waste liquid) previously used to culture animal cells is used to culture algae; (ii) a step in which the algae is collected, mixed with a solid catalyst, and heated, and an algae extract is thereby obtained; (iii) a step in which the algae extract is added to the waste liquid (a second waste liquid) previously used to culture algae in (i), the concentration of the algae extract is adjusted, and a composition for culturing animal cells is produced; and (iv) a step in which animal cells are cultured using the composition for culturing animal cells.
The present invention provides an algae culturing method in which a composition containing a medium that has been used to culture animal cells is used as a medium. The present invention further provides a composition for culturing algae, the composition containing a medium that has been used to culture animal cells. Moreover, the present invention provides an algae and animal cell recycle culturing method.
C12N 1/12 - Algues unicellulairesLeurs milieux de culture
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
14.
PRODUCTION METHOD FOR COMPOSITION FOR CELL CULTURING, COMPOSITION FOR CELL CULTURING OBTAINED BY SAME, AND CELL CULTURING METHOD USING SAME
The present invention provides a production method for a composition for cell culturing. This production method comprises: (1) a step for subjecting algae to an acid hydrolysis treatment and/or an alkali hydrolysis treatment; (2) a step for neutralizing the hydrolysis product obtained in the step (1) to obtain an algae extract; and (3) a step for mixing the algae extract with a medium for cell culturing, wherein the medium for cell culturing does not substantially contain L-glutamine.
Disclosed is a method for acquiring information on spinal muscular atrophy, comprising acquiring a fluorescence image of a nucleated cell in a measurement sample, wherein the measurement sample is a sample prepared from a blood specimen obtained from a subject, an SMN protein in the nucleated cell is labeled with a first fluorescent dye, and a predetermined nuclear protein in the nucleated cell is labeled with a second fluorescent dye, acquiring an intracellular distance between a first bright spot corresponding to the first fluorescent dye and a second bright spot corresponding to the second fluorescent dye in the fluorescence image, and acquiring a value regarding a number of nucleated cells in which the intracellular distance is equal to or less than a first threshold value, wherein the value is an indicator of spinal muscular atrophy affection.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A S100A8-inhibiting peptide comprises (A) a peptide which comprises a portion of the amino acid sequence represented by SEQ ID NO: 1, contains an alanine (Ala) residue located at position-5 from the N-terminal of the aforementioned amino acid sequence, and has a length composed of 5 to 10 residues or (B) a peptide which comprises the amino acid sequence represented by SEQ ID NO: 2.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
A conventional example (FFR-CT) regarding measurement of coronary fractional flow reserve (FFR) from a coronary artery 3D model by a simulation based on numerical fluid dynamics, has limitations such as the inability to perform analysis of a subject having coronary artery calcification or stent placement. In addition, FFR-CT is merely a calculation based on static information, and the hardness and the distensibility of the coronary artery wall are not taken into account. The present invention provides a functional ischemia detection system or the like capable of calculating instantaneous flow reserve iFR (in the present invention, CT-iFR) and non-invasively detecting functional ischemia, by: reconstructing, by using a predictive interpolation technique, multi-time phase CCTA data obtained by coronary artery contrast CT; obtaining temporal concentration curves of a coronary artery proximal portion and a coronary artery distal portion from the reconstructed CCTA data; and quantifying coronary artery flow using a mathematical model (a maximum slope method, a convolution integral method, or the like).
The objective of the present invention is to improve the quality and strength of a tubular cell structure produced only from cells. The representative configuration of the method for culturing a tubular cell structure according to the present invention is characterized in that cells are formed into a tubular cell structure, and the cell structure is cultured while expanding the cell structure from the lining of the cell structure by a balloon toward the outside in the radial direction.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
19.
AUTOMATED SURGERY PLANNING SYSTEM, SURGERY PLANNING METHOD, AND PROGRAM
[Problem] To provide an automated surgery planning system which can reduce a physician's load by eliminating manual setting of anatomical landmarks in medical image data. [Solution] According to one aspect of the present embodiment, an automated surgery planning system is provided. The automated surgery planning system is configured so as to execute the following steps. In a readout step, medical image data in which a subject's bone structure can be retained or reproduced as information is read out. In a specification step, the medical image data is input into a pre-stored machine learning model to extract at least one anatomical landmark in the medical image data, thereby specifying the location of the anatomical landmark in the subject's bone structure.
The present invention is a surgery-assisting device characterized by comprising: a sleeve provided with a proximal-end linear part, a distal-end linear part, and a bent part which is arcuate in side view and which is provided between the proximal-end linear part and the distal-end-side linear part; an arc track rail for retaining the bent part so that the bent part can slide along the direction of the arc shape thereof; a rail-retaining arm for retaining the arc track rail; a rotating bearing for supporting the rail-retaining arm while allowing the rail-retaining arm to rotate; and an operating arm which extends into the sleeve, the proximal-end linear part and the distal-end linear part being positioned on a substantially straight line, and the center of curvature of the bent part being on a line of extension of the proximal-end linear part and the distal-end linear part and on the rotational axis of the rotating bearing.
The present invention provides a production method for a composition for cell culturing. This production method comprises: (1) a step for subjecting algae to an acid hydrolysis treatment and/or an alkali hydrolysis treatment; (2) a step for neutralizing the hydrolysis product obtained in the step (1) to obtain an algae extract; and (3) a step for mixing the algae extract with a medium for cell culturing, wherein the medium for cell culturing does not substantially contain L-glutamine.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 1/12 - Algues unicellulairesLeurs milieux de culture
22.
SHEET FOR COVERING WOUND, AND METHOD FOR COVERING WOUND
A sheet for covering a wound includes a laminate of a serosal membrane and a cell sheet. The sheet for covering a wound has a proper thickness and strength. The sheet does not flow out from the wound site and can be fixed to the wound site by suture or anastomosis, if necessary. The sheet can be stably engrafted onto a wound region.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
The present invention provides a tubular tissue preparation device provided with: a chamber for accommodating a tubular support body; a first support part for communicating the inside and the outside of the chamber and fixing the tubular support body; and a pressurizing/depressurizing means for controlling the pressure in an inner space of the chamber, wherein the first support part is for fixing a first opening section of the tubular support body, communicating a lumen of the tubular support body and the outside of the chamber, and separating the lumen of the tubular support body and the inner space of the chamber. Also, the present invention provides a tubular tissue preparation kit that includes said device and a device for transporting sheet-shaped tissue. In addition, the present invention provides a tubular tissue preparation method using said device.
The present invention relates to a therapeutic substance delivery device for delivering a therapeutic substance to a desired site in a bodily duct, characterized in that the therapeutic substance delivery device is provided with: a therapeutic substance loading portion; a connector which is connected to the therapeutic substance loading portion; and a supplying/discharging pipe connected to the connector; and in that the therapeutic substance loading portion includes a main body portion in which a recessed portion is formed, a resilient film, and a connecting pipe; the connector is provided with a joint main body, a flange portion fixed to the other end portion side of the joint main body, and a fixing nut through which the joint main body passes; the joint main body is provided with a tube fastening portion; and at least part of the inner wall of the fixing nut is provided with a thread.
Provided are: a therapeutic agent for urological cancer, particularly urological cancer with a reduced function of lysine (K)-specific demethylase 6A (KDM6A), which is characterized by inhibiting both IL-6 activity and CCR2/CCL2 activity; and a therapeutic method.
A cell culture container may include an inlet through which a fluid is supplied, an outlet through which a fluid is discharged, and a flow path configured to connect the inlet to the outlet and accommodate a cell culture substrate containing gold nanoparticles and capable of being denatured by heating.
The presently disclosed subject matter is to provide a hepatocyte structure, particularly, a hepatocyte structure that mimics nonalcoholic steatohepatitis (NASH).
The presently disclosed subject matter is to provide a hepatocyte structure, particularly, a hepatocyte structure that mimics nonalcoholic steatohepatitis (NASH).
A hepatocyte construct including an aggregate containing hepatocytes and adherent cells that are non-hepatocytes, and wherein the hepatocytes include ballooned hepatocytes is provided. Further, a method for producing a hepatocyte construct, comprising: (i) forming an aggregate by aggregating a cell group comprising hepatocytes and adherent cells that are non-hepatocytes; and (ii) culturing the aggregate is provided.
The purpose of the present invention is to enable preventing aging or extending the life of a human or nonhuman organism with a method other than restricting calories or administering metformin. It is possible to prevent aging or extend the life of a human or nonhuman organism by administering an agent that contains A) a xanthine oxidase/xanthine dehydrogenase inhibitor. It is further possible to prevent aging or extend the life of a human or nonhuman organism by combining A) the xanthine oxidase/xanthine dehydrogenase inhibitor and B) hypoxanthine or a compound that can be converted to hypoxanthine in the body, and administering these simultaneously or administering these as a mixed agent or kit agents.
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 31/708 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique ayant des groupes oxo liés directement au système cyclique purine, p. ex. guanosine, acide guanylique
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
29.
Method for producing layered cell sheet and layered cell sheet produced by the same
The present invention provides a method for swiftly producing a layered cell sheet that is non-invasively obtained and is utilizable for transplantation, etc., the method including (1) a step of applying a centrifugal force to a first cell sheet on a temperature-responsive culture surface for a predetermined time in a temperature range from a lower critical solution temperature of the temperature-responsive culture surface to 45° C., (2) a step of further placing a second cell sheet on the first cell sheet, and (3) a step of applying a centrifugal force to the first cell sheet and the second cell sheet on the temperature-responsive culture surface for a predetermined time in the temperature range from the lower critical solution temperature to 45° C.; and also provides a layered cell sheet obtained by the method.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
30.
TOPICAL COMPOSITION CONTAINING EXTRACELLULAR VESICLES PRODUCED BY BUCCAL EPITHELIAL CELLS
The present invention provides a novel topical composition that can be easily manufactured and is capable of improving the state of bodily tissue, especially epithelial tissue such as the skin or mucosae. In particular, the present invention provides a topical composition containing extracellular vesicles derived from buccal epithelial cells.
A61K 35/36 - PeauSystème pileuxOnglesGlandes sébacéesCérumenÉpidermeCellules épithélialesKératinocytesCellules de LangerhansCellules ectodermiques
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
The present invention addresses the problem of producing a large quantity of myocardial cells with high efficiency. Provided is a method for producing myocardial cells, comprising the steps of: (1) subjecting iPC cells to spheroid culture using a culture substratum having multiple compartments so that multiple embryoid bodies can be spheroid-cultured in an individually separated state, thereby forming multiple embryoid bodies; and (2) subjecting the multiple embryoid bodies produced in step (1) to three-dimensional suspension culture to induce the differentiation of the multiple embryoid bodies into myocardial cells.
As a conventional example of an electrocardiogram diagnostic support method, methods have been proposed in which the learning stage is divided into two stages and a two-stage learning model is generated, but such models learn binary classification models that output 'normal' or 'abnormal' and output only whether the waveform of the ECG image indicates an abnormality, so do not determine an actual diagnosis (disease name, sickness name, etc.). In the present invention, an electrocardiogram diagnostic device is provided which uses training data comprising diagnoses ('normal', or multiple sickness names (disease names)) attached to electrocardiogram images to learn a model that, in addition to 'normal', can output disease names through machine learning such as CNN, LSTM, etc. By giving electrocardiogram images obtained in an actual test to a model that has been learned, the electrocardiogram diagnostic device outputs a diagnosis ('normal', or disease names) that can be obtained by reading the electrocardiogram image.
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
A61B 5/0452 - Détection de paramètres spécifiques du cycle de l'électrocardiogramme
One embodiment of the present disclosure is provided with: an information acquisition portion; an information storage portion; an event extraction section; a region setting section; and a display section. The information storage portion adds, to medical information, a time at which the information acquisition portion acquires the medical information from each of multiple medical devices used in a surgery, and a label for specifying the medical information. The display section causes a display device to display, as medical information, an image including a surgery site and at least one event extracted by the event extraction section in a time region set by the region setting section based on the time added to the medical information.
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
G06F 3/14 - Sortie numérique vers un dispositif de visualisation
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
This cell culture container is filled with a cell culture matrix (14) including: a gel layer which is formed of a gel (15) denatured by heating; and a gold fine particle layer (13) which is formed on one surface of the gel layer, wherein cells are cultured on the one surface side of the cell culture matrix or on the other surface side thereof. This cell culture container manufacturing method comprises: a step for filling the cell culture container with a gel denatured by heating; and a step for forming a gold fine particle layer on one surface of the gel. This cell acquisition method comprises: a step for selecting cells to be acquired from among cells placed in the cell culture container; a step for emitting light onto a cell culture matrix in the vicinity of the selected cells; and a step for collecting the selected cells.
The present invention provides an angiogenesis inhibitor containing as an active ingredient LYPD1 protein or a derivative thereof, a part thereof, or a vector expressing the same, or a cell expressing the same. The present invention also provides a screening method for angiogenesis inhibitors that enhance the expression of LYPD1 protein wherein the method includes (i) a step for treating a first cell by a test substance and culturing and (ii) a step for detecting the expression level of LYPD1 protein from the first cell and comparing with the level of LYPD1 protein of an untreated first cell.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present invention provides a tubular tissue preparation device provided with: a chamber for accommodating a tubular support body; a first support part for communicating the inside and the outside of the chamber and fixing the tubular support body; and a pressurizing/depressurizing means for controlling the pressure in an inner space of the chamber, wherein the first support part is for fixing a first opening section of the tubular support body, communicating a lumen of the tubular support body and the outside of the chamber, and separating the lumen of the tubular support body and the inner space of the chamber. Also, the present invention provides a tubular tissue preparation kit that includes said device and a device for transporting sheet-shaped tissue. In addition, the present invention provides a tubular tissue preparation method using said device.
The present invention provides a method for predicting the onset of glioma in a subject. Specifically, the present invention provides a method for predicting the onset of glioma in a subject, wherein the method is characterized by including: (1) a step for detecting vimentin in a blood serum sample derived from the subject; and (2) a step for predicting, when vimentin is detected, that there is a high possibility that the subject suffers from glioma.
A device for measuring a tension of a sheet-like tissue containing cardiomyocytes includes a first gel adapter holder having a frame member and a first gel holding member protruding toward a part of an inside face of the frame member for fixing one end of a film-like gel; and a second gel adapter holder having a second gel holding member for fixing the other end of the gel and a connection member connected to the second gel holding member. A kit includes the tension measuring device; a substrate having a pair of gel molding protruding members fitted along the inside face of the frame member; and a gel forming lid body having a face parallel to a gel contact face of the substrate so as to form an upper face of the gel. Further, a system for measuring the tension includes the tension measuring device.
G01N 13/02 - Recherche de la tension superficielle des liquides
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
B01L 9/00 - Dispositifs de supportDispositifs de serrage
39.
CELL CULTURE CONTAINER, CELL RECOVERY SYSTEM, METHOD FOR OBTAINING CELL, AND METHOD FOR CULTURING CELL
OSAKA PREFECTURE UNIVERSITY PUBLIC CORPORATION (Japon)
TOKYO WOMEN'S MEDICAL UNIVERSITY (Japon)
NIKON CORPORATION (Japon)
Inventeur(s)
Kojima Chie
Shimizu Tatsuya
Haraguchi Yuji
Kawano Takeshi
Taki Yusuke
Yokoyama Kaede
Abrégé
A cell culture container having a plurality of wells, wherein each well is filled with a cell culture substrate in which gold fine particles are dispersed in a gel that is denatured by heating. A method for obtaining a cell, including a step for selecting a cell to be obtained from cells disposed in wells of the cell culture container, a step for radiating light to a cell culture substrate filling a well of the cell culture container in which the cell to be obtained is disposed, a step for extracting the cell culture substrate from the cell culture container, and a step for recovering a cell from the gel extracted from the cell culture container.
OSAKA PREFECTURE UNIVERSITY PUBLIC CORPORATION (Japon)
TOKYO WOMEN'S MEDICAL UNIVERSITY (Japon)
NIKON CORPORATION (Japon)
Inventeur(s)
Kojima Chie
Shimizu Tatsuya
Haraguchi Yuji
Kawano Takeshi
Taki Yusuke
Yokoyama Kaede
Abrégé
Provided is a cell culture container equipped with an inlet (21) for injecting a fluid, an outlet (22) for discharging a fluid, and a flow path (23) that connects the inlet and the outlet and accommodates a cell culture substrate (14) obtained by dispersing gold microparticles (13) in a gel denatured by heating. Also provided is a method for acquiring cells, the method including a step for selecting cells to be acquired from cells cultured in the cell culture container, a step for irradiating the gel with light in the vicinity of the selected cells, a step for allowing a liquid to flow into the flow path of the cell culture container, and a step for recovering cells from the outlet of the cell culture container.
The present invention provides a method for swiftly producing a layered cell sheet that is non-invasively obtained and is utilizable for transplantation, etc., the method including (1) a step of applying a centrifugal force to a first cell sheet on a temperature-responsive culture surface for a predetermined time in a temperature range from a lower critical solution temperature of the temperature-responsive culture surface to 45℃, (2) a step of further placing a second cell sheet on the first cell sheet, and (3) a step of applying a centrifugal force to the first cell sheet and the second cell sheet on the temperature-responsive culture surface for a predetermined time in the temperature range from the lower critical solution temperature to 45℃; and also provides a layered cell sheet obtained by the method.
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
COMPOSITION HAVING ESTROGEN-LIKE ACTION, MEDICINE, FOOD AND BEVERAGE CONTAINING SAME, METHOD FOR PRODUCING COMPOSITION HAVING ESTROGEN-LIKE ACTION AND METHOD FOR UTILIZING DNA BASE SEQUENCE OF SPARASSIS CRISPA
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
Provided is a LYPD1 inhibitor for promoting vascular endothelial network formation in a biological tissue. Also provided is a medicinal composition, said medicinal composition comprising a LYPD1 inhibitor as an active ingredient, for treating and/or preventing neoangiogenic disorders. Also provided is a method which comprises: (a1) a step for providing a cell population containing first cells expressing LYPD1 and vascular endothelial cells; (a2) a step for treating the cell population obtained in step (a1) with a LYPD1 inhibitor; and (a3) a step for culturing the cell population obtained in step (a2).
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
44.
Method for reducing pluripotent stem cells, method for producing cell population having reduced pluripotent stem cells
The present invention pertains to a method for culturing a cell population including pluripotent stem cells and differentiated cells derived from pluripotent stem cells at a temperature of 40.5° C. or higher and reducing the pluripotent stem cells included in the cell population. The present invention also pertains to a method for reducing pluripotent stem cells from a cell population including pluripotent stem cells and differentiated cells derived from pluripotent stem cells, wherein the method includes a step for activating the TRPV-1 expressed in the pluripotent stem cells included in the cell population. The present invention makes it possible to reduce the pluripotent stem cells remaining in an undifferentiated state when inducing the differentiation of a pluripotent stem cell population.
Provided is a puncturing instrument capable of administering (supplying) a liquid drug. The puncturing instrument comprises: a puncturing tip (2); a first tubular body (3) connected to the puncturing tip (2) at the distal end thereof; and an outside tubular body (5) covering at least part of the first tubular body (3). The first tubular body (3) is formed so as to be rotatable around a shaft in the longitudinal direction. The outer diameter of the first tubular body (3) is smaller than the inner diameter of the outside tubular body (5) and a liquid drug supply path (5a) is provided on the outside of the first tubular body (3).
One embodiment of the present disclosure is provided with: an information acquisition unit (30, 40-50); an information storage unit (30); an event extraction unit (72, S406); a region setting unit (72, S404); and a display unit (72, S408, S412, S416, S420, S424). The information storage unit adds, to medical information, a time at which the information acquisition unit acquires the medical information from each of a plurality of medical devices (102-112) used for surgery, and a label for specifying the medical information. The display unit causes a display device (74) to display, as medical information, an image including a surgery site and at least one event extracted by the event extraction unit in a time region set by the region setting unit on the basis of the time added to the medical information.
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
47.
Method for culturing animal cell composition, method for producing animal cell composition using same, and animal cell composition
An object of the present invention is to obtain a thicker animal cell composition by a simple and less expensive method. Namely, an object of the present invention is to provide a method for culturing a thicker animal cell composition by eliminating the hypoxia associated with animal cell compositions, a method for producing an animal cell composition containing unicellular algae, and an animal cell composition.
The present invention provides a method for culturing an animal cell composition in a culture medium in the presence of unicellular algae and under exposure to light. According to the method of the present invention, oxygen can be continuously supplied in the culture medium, cell damage is alleviated, and a thicker cell composition can be obtained in the absence of a capillary network.
C12N 1/12 - Algues unicellulairesLeurs milieux de culture
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A measuring apparatus relates to a contractile ability of a spontaneously pulsating myocardial tissue. The measuring apparatus includes a measurement table and a pressure sensor. The measurement table includes a storage section having an opening and configured to hold liquid inside the storage section, and an attaching portion on which the myocardial tissue is attached around the opening. The pressure sensor is disposed inside the storage section.
The purpose of the present invention is to provide a method capable of analyzing an SMN protein nuclear body that serves as a more highly reliable biomarker. The method according to the present invention is a method for analyzing the expression of an SMN protein nuclear body, and comprises the steps of: labeling at least one surface antigen marker for blood-derived nucleated cells with at least one labeling antibody in a sample containing the nucleated cells; labeling the SMN protein in the nucleated cells; labeling the nuclei of the nucleated cells; selecting one cell mass from among multiple cell masses of the nucleated cells, the multiple cell masses being cell masses in which the nucleus and the SMN protein are labeled and which have been classified on the basis of the surface antigen marker labeled with the labeling antibody or the like; and subjecting the selected cell mass to analysis on the expression of the SMN protein nuclear body on the basis of the labeling of the SMN protein. The method involves carrying out imaging flow cytometry using an objective lens at a specific magnification.
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
G01N 33/536 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
50.
CELL SHEET COMPOSITION INCLUDING MESENCHYMAL STEM CELLS, AND METHOD FOR HEALING LUMINAL ORGAN USING SAME
The present invention addresses the problem of providing a cell sheet composition for healing or preventing discharge from a wounded region of a luminal organ. The present invention also addresses the problem of providing a method in which the cell sheet composition is affixed to a wounded region of a luminal organ to heal or prevent discharge from the wounded region of the luminal organ. The present invention provides a cell sheet composition including mesenchymal stem cells which is characterized by being affixed to a wounded region of a luminal organ in order to heal or prevent discharge from the wounded region of the luminal organ. The present invention also provides a method in which the cell sheet composition including mesenchymal stem cells is affixed to a wounded region of a luminal organ to heal or prevent discharge from the wounded region of the luminal organ.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
51.
METHOD FOR PRODUCING LAYERED CELL SHEET COMPOSITION, LAYERED CELL SHEET COMPOSITION PRODUCED USING SAME, AND DEVICE FOR PRODUCING SAME
The present invention provides a method for producing a layered cell sheet composition, the method including a step for bringing a cultured cell movement jig into contact with an upper surface of a sheet-like cell group so that a first cell sheet adheres to the cultured cell movement jig, a step for applying a cell adhesive substance to an upper surface of a second sheet-like cell group, and/or a lower surface of the first cell sheet adhered to the cultured cell movement jig, and a step for bringing the lower surface of the first cell sheet adhered to the cultured cell movement jig, into contact with the upper surface of the second sheet-like cell group so that a second cell sheet is adhered to the first cell sheet. The present invention also provides a layered cell sheet composition produced using the method. The present invention also provides a device for producing the layered cell sheet composition.
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12M 3/04 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des couches minces
The present invention addresses the problem of providing a collagen production inhibitor, which comprises as an active ingredient a low-molecular compound having an effect of effectively inhibiting (preventing) collagen production, and a prophylactic or therapeutic agent for skin fibrotic diseases which is capable of effectively preventing or treating skin fibrotic diseases. A preparation comprising one or more members selected from compounds represented by formulae (1) and (2) and salts thereof is used as a collagen production inhibitor or a prophylactic or therapeutic agent for skin fibrotic diseases.
The present invention relates to a therapeutic substance delivery device for delivering a therapeutic substance to a desired site in a bodily duct, characterized in that the therapeutic substance delivery device is provided with: a therapeutic substance loading portion; a connector which is connected to the therapeutic substance loading portion; and a supplying/discharging pipe connected to the connector; and in that the therapeutic substance loading portion includes a main body portion in which a recessed portion is formed, a resilient film, and a connecting pipe; the connector is provided with a joint main body, a flange portion fixed to the other end portion side of the joint main body, and a fixing nut through which the joint main body passes; the joint main body is provided with a tube fastening portion; and at least part of the inner wall of the fixing nut is provided with a thread.
The present invention pertains to a method for culturing a cell population including pluripotent stem cells and differentiated cells derived from pluripotent stem cells at a temperature of 40.5°C or higher and reducing the pluripotent stem cells included in the cell population. The present invention also pertains to a method for reducing pluripotent stem cells from a cell population including pluripotent stem cells and differentiated cells derived from pluripotent stem cells, wherein the method includes a step for activating the TRPV-1 expressed in the pluripotent stem cells included in the cell population. The presesnt invention makes it possible to reduce the pluripotent stem cells remaining in an undifferentiated state when inducing the differentiation of a pluripotent stem cell population.
The present invention addresses the problem of obtaining an animal cell composition having a certain thickness by a simple and low-cost method. Specifically, the purpose of the present invention is to provide a method for eliminating the hypoxic state of an animal cell composition, and culturing an animal cell composition having a certain thickness, a method for producing an animal cell composition containing unicellular algae, and an animal cell composition. The present invention provides a method for culturing an animal cell composition in a liquid culture medium while irradiating the liquid culture medium with light in the presence of unicellular algae. According to the present invention, oxygen can be continuously supplied to the liquid culture medium, and a cell composition which has a certain thickness can be obtained without having a capillary network and in which damage to cells can be reduced.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 1/12 - Algues unicellulairesLeurs milieux de culture
A determination device is provided with a determination unit for determining the state of a cell using information on uniformity of a detection target generated on the basis of light intensity of light emitted from the detection target included in biological cells that have been irradiated with excitation light. In the determination device, the detection target may be a protein. In addition, the determination device may be provided with an information generating unit for generating information, wherein the information generating unit may generate information in which information corresponding to a non-resonant background signals is removed.
Provided are layered cell sheets, comprising a plurality of layered cell sheets containing myoblasts, in which each cell sheet comprises cell population containing myoblasts with controlled orientations. Preferably provided are the layered cell sheets comprising a region in which the orientations of the cell population containing the myoblasts in each cell sheet are identical to each other.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
A61L 27/16 - Matériaux macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
58.
Middle ear mucosa-like cell sheet, process of producing the same and method of using the same
The purpose of the present invention is to obtain an alternative to a substitute of the mucosa in the middle ear which is engrafted on the surface of the bone in the middle ear, hyperplasia of the granulation tissue and the bone and the development of the fibroblast cells in the middle ear are suppressed, and to obtain a middle ear mucosa-like cell sheet retaining cilia in the surface layer, comprising culturing nasal epithelium cells on a cell culture substrate coated with a polymer whose hydration force changes within a temperature range of 0 to 80° C., wherein the cells are cultured within a temperature range where the hydration force of the polymer is weak, and then changing the temperature to a temperature at which the hydration force is strong to recover the cultured cell sheet.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
59.
PHOTOSENSITIVE COMPOSITION, PATTERNED SUBSTRATE, CELL CULTURE SUPPORT, AND CULTURED CELL PRODUCTION METHOD
The present invention provides a photosensitive composition which includes a copolymer containing constitutional units represented by formulae (1)-(3), a photoacid generator, and a solvent (the definition of the groups in the formulae is as described in the specification).
The present invention provides a cancer therapy method having reduced adverse side effects. Specifically, an anti-cancer agent comprising an anthracycline is used in such a manner that the anthracycline can be administered to a cancer patient at a dose of 0.5 to 7.5 mg/kg body weight in a combination therapy of a high intensity focused ultrasound therapy at a radiation intensity of 320 to 700 W/cm2 and an anti-cancer agent therapy.
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
The present invention enables statistical analysis of clinical data with a small number of samples. The following steps are included: a model generation step for performing iterative analysis of factor information items of patients which relate to the occurrence of adverse effects and which include an inspection value before dosing, and for modeling the trend of inspection values after dosing; and a distribution generation step for virtually generating, from the patient factor information items for which the inspection value trend has been modelled, patient factor-information items having the same factor information items as the patient factor-information items, and generates a frequency distribution for each of the factor information items for the patients for whom the fluctuation in the inspection values due to dosing is at or above a certain level, from among the patients having the generated factor information.
NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (Japon)
Inventeur(s)
Hanawa, Takao
Tsutsumi, Yusuke
Tsumanuma, Yuka
Suphanantachat, Supreda
Yano, Kosei
Abrégé
Provided is an implant cultured periodontal ligament cell sheet complex that can be satisfactorily fixed to a bone with periodontal ligament tissue interposed therebetween. A dental implant fixture part is coated with calcium phosphate, and a cultured periodontal ligament cell sheet is brought into intimate contact with the implant.
The present invention provides a method for predicting the onset of glioblastoma in a test subject. The present invention is a method characterized by including: (1) a step for measuring the nestin concentration in a blood sample drawn from a test subject; and (2) a step for predicting a high likelihood that the test subject is suffering from glioblastoma, in the event that the nestin concentration is 0.63 ng/mL or above, and preferably 1.00 ng/mL or above.
Provided is a method for detecting the expression of SMN protein, said method comprises: a step for labeling SMN protein in a sample, said sample containing nucleated cells derived from blood; a step for labeling the nuclei of the nucleated cells in the sample; a step for selecting cell masses wherein the nuclei of the nucleated cells and the SMN protein are labeled; and a step for detecting the expression of the SMN protein on the basis of the label bound to the SMN protein in the cell masses that are selected above.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
65.
Cell culture apparatus and cell culture method using the same
Disclosed herein is a cell culture apparatus that can achieve appropriate culture conditions. The cell culture apparatus (1) includes: a cylindrical culture vessel (10) that holds a culture liquid containing cells; a supporting column (20) that stands upright in a center of an inner surface of a bottom (12) in the culture vessel; and a stirring device (30) that includes an attaching portion (32) that is attached to an upper portion of the supporting column so as to be rotatable relative to the supporting column and a stirring blade (34) whose upper portion is fixed to the attaching portion so as to rotate around the supporting column.
Provided is a cell culturing device capable of having a simple configuration and performing cell culturing well. The cell culturing device (5) comprises: a culture tank (15) housing a culture solution including cells; a shaft member (17) having at least part thereof arranged inside the culture tank (15); an agitation mechanism (19) supported by the shaft member (17), arranged inside the culture tank (15), and having at least a pair of agitation blades (27) rotatably provided that have the shaft member (17) as the rotation center thereof; and a filter (21) provided so as to come in contact with the shaft member (17) and attracting the culture solution from the culture tank (15) and/or supplying the culture solution to the culture tank (15). The shaft member (17) is at least partially hollow, has openings (17a, 17b) provided that guide the culture solution therein or guide the culture solution out from the interior thereof, cannot rotate, and draws the culture solution from the culture tank (15) and/or supplies the culture solution to the culture tank (15), via the filter (21) and the interior of the shaft member (17).
C12M 3/02 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des suspensions
C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
A cell culture system having a cell culture vessel, a composition controlling fluid storage vessel, a culture fluid composition controlling means having an inlet and an outlet for a cell culture fluid, an inlet-connected fluid feeding circuit from the cell culture vessel to the inlet of the culture fluid composition controlling means, an outlet-connected fluid feeding circuit from the cell culture vessel to the outlet of the culture fluid composition controlling means, a means which perfuses the cell culture fluid from the inlet-connected fluid feeding circuit to the outlet-connected fluid feeding circuit through the culture fluid composition controlling means, and a means which controls the amount of fluid in the cell culture vessel, in which compositions of the cell culture fluid in the cell culture vessel and compositions of the composition controlling fluid in the composition controlling fluid storage vessel can be controlled in a continuous manner.
The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A61K 35/22 - UrineAppareil urinaire, p. ex. rein ou vessieCellules mésangiales intraglomérulairesCellules mésenchymateuses rénalesGlande surrénale
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
Provided is a cell culture method. Cells are cultured using a medium that is substantially serum-free and contains (A) a retinoid and (B) an interleukin-1 inhibitor and/or a calpain inhibitor.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
70.
Method of evaluating wetting characteristic of object
Provided is a means for evaluating the wetting characteristic of an object such as a cell sheet and a culture dish in a non-contact fashion. The wetting characteristic of an object is evaluated by a method comprising the steps of: (1) removing a liquid by jetting a gas at a surface of the object covered with the liquid, (2) measuring a dimension of a region in which the liquid is removed after the completion of the gas jetting and (3) evaluating the wetting characteristic of the object using the measured dimension as an index.
G01N 33/483 - Analyse physique de matériau biologique
G01N 13/00 - Recherche des effets de surface ou de couche limite, p. ex. pouvoir mouillantRecherche des effets de diffusionAnalyse des matériaux en déterminant les effets superficiels, limites ou de diffusion
G01N 13/02 - Recherche de la tension superficielle des liquides
71.
Apparatus for supporting and following movement of a part of person's body
An apparatus includes a brace being mounted on a person's body part and having a hard fitting surface. The apparatus also includes a load device, a support, a securing member, a brake, a switch device, and a soft film. The load device has a hard receiving surface receiving the fitting surface of the brace. The support movably supports the load device. The securing member secures the fitting surface to the receiving surface and enables the load device to move and follow movement of the person's body part and the brace against resistance applied from the support. The brake limits movement of the load device. The switch device switches operation modes of the apparatus, at least, between a free mode and a limiting mode. The soft film is arranged between the receiving and fitting surfaces for smooth movement of the person's body part on the load device in the limiting mode.
A47F 5/00 - Stands d'étalage, systèmes de suspension ou rayonnages caractérisés par leurs particularités de structure
A61B 19/00 - Instruments, outillage ou accessoires pour la chirurgie ou le diagnostic non couverts par l'un des groupes A61B 1/00-A61B 18/00, p.ex. pour stéréotaxie, opération aseptique, traitement de la luxation, protecteurs des bords des blessures(masques de protection du visage A41D 13/11; blouses de chirurgien ou vêtements pour malades A41D 13/12; dispositifs pour retirer, traiter ou transporter les liquides du corps A61M 1/00)
F16M 11/12 - Moyens pour la fixation des appareilsMoyens permettant le réglage des appareils par rapport au banc permettant la rotation dans plus d'une direction
F16M 11/04 - Moyens pour la fixation des appareilsMoyens permettant le réglage des appareils par rapport au banc
F16M 11/06 - Moyens pour la fixation des appareilsMoyens permettant le réglage des appareils par rapport au banc permettant la rotation
F16M 11/24 - Infrastructure avec ou sans roues à hauteur ou longueur modifiables des pieds, avec utilisation possible pour le transport également
This cell sheet laminate, which results from laminating a plurality of layers of cell sheets containing myoblasts, is characterized by each cell sheet containing a cell group containing myoblasts of which the orientation has been controlled. Preferably, the cell sheet laminate has a region at which the orientations of the cell groups containing myoblasts of each sheet are the same as each other.
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12M 3/04 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des couches minces
73.
Temperature-responsive substrate for cell culture and production method thereof
B05D 1/00 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
The purpose of the present invention is to create an immune-tolerance inducer used in therapy in which donor hematopoietic cells are transplanted into a recipient in order to induce immune tolerance in the recipient with respect to donor cells, tissue, or organs. By using an alpha-galactosylceramide-containing liposome in combination with a costimulatory-pathway-blocking substance, hematopoietic chimerism can be induced in the recipient by the transplantation of donor hematopoietic cells, making it possible to induce immune tolerance in the recipient with respect to donor cells, tissue, or organs.
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c.-à-d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p. ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
75.
SHEET SHAPED THERAPEUTIC-USE SUBSTANCE CONVEYANCE APPARATUS, AND METHOD FOR AFFIXING SHEET SHAPED THERAPEUTIC-USE SUBSTANCE
The purpose of the present invention is to precisely affix a sheet shaped therapeutic-use substance inside of a living organism. In the present invention, as shown in fig. 6(a), a sheet-shaped substance (40), in a state where wrinkles are formed therein, can be fit to a head (70). In such case, if the sheet-shaped substance (40) comes into contact with the outer peripheral portion of the head (70), the sheet-shaped substance (40) can be made to disperse, as shown in fig. 6(b), by making the pressure inside of a ventilation hole (71) positive. The surface of the head (70) has a protruding shape and therefore this surface is roughly parallel to the inner surface of an esophageal wall (300) to which the sheet-shaped substance (40) is to be affixed. As a result, such affixing (fig. 6(b)), in particular, can be carried out with greater precision.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
C07C 251/86 - Hydrazones ayant des atomes de carbone, liés par des liaisons doubles, de groupes hydrazone liés à des atomes de carbone de cycles aromatiques à six chaînons
C07C 43/225 - Éthers une liaison sur l'oxygène de la fonction éther étant sur un atome de carbone d'un cycle aromatique à six chaînons contenant des atomes d'halogène
An automated culturing device, which uses culturing vessels having flat culturing surfaces, the automated culturing device being characterized: by having multiple levels of culturing vessel-holding shelves that hold multiple culturing vessels at intervals in the height direction, which is perpendicular to the culturing surface; by each of the culturing vessel-holding shelves holding the respective culturing vessels during culturing; and by being equipped with sensors, which are provided at each culturing vessel-holding shelf and are for detecting a posture or vibration of the shelf, and a drive system, which is capable of changing the posture of each culturing vessel-holding shelf between either a horizontal state or an inclined state in accordance with the sensor signal and maintains the horizontality of each culturing vessel-holding shelf during cell culturing.
The present invention provides a method for producing a myocardial sheet using a group of cells derived from embryonic stem cells. This method is characterized by mixing Flk/KDR positive cells, cardiomyocytes, endothelial cells, and mural cells, all derived from embryonic stem cells, and culturing the mixed cells. Furthermore, the myocardial sheet can be used as a therapeutic agent for heart diseases since VEGF is released from the sheet.
Provided is a cell culture apparatus capable of actualizing a suitable culture environment. The cell culture apparatus (1) is provided with a cylindrical culture vessel (10) housing a culture medium containing cells; a support (20) standing upright from the center of the inner surface of the bottom (12) inside the culture vessel; and a stirring means (30) having an attaching portion (32) mounted, rotatably relative to the support, on the upper part of the support, and an impeller (34), the upper part of which is secured to the attaching portion, that rotates with the support as the rotation center.
C12M 3/02 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des suspensions
C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
Provided is a means of non-contact evaluation of the wettability of an object such as a cell sheet or culture dish. The wettability of the object is evaluated by means of a method containing: (1) a step in which a gas is emitted onto the surface of the object, which is covered by a liquid, thereby removing the liquid; (2) a step in which, after the gas has been emitted, a dimension is measured, said dimension being of the area from which the liquid was removed; and (3) a step in which the wettability of the object is evaluated using the measured dimension as an index.
G01N 13/00 - Recherche des effets de surface ou de couche limite, p. ex. pouvoir mouillantRecherche des effets de diffusionAnalyse des matériaux en déterminant les effets superficiels, limites ou de diffusion
The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material.
C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A cell culture system equipped with a cell culture vessel, a composition-adjusted solution storage vessel, a culture solution composition adjustment means which has an inlet port and an outlet port for a cell culture solution, an inlet-connected liquid feeding circuit which is connected from the cell culture vessel to the inlet port of the culture solution composition adjustment means, an outlet-connected liquid feeding circuit which is connected from the cell culture vessel to the outlet port of the culture solution composition adjustment means, a means for perfusing the cell culture solution from the inlet-connected liquid feeding circuit to the outlet-connected liquid feeding circuit via the culture solution composition adjustment means, and a means for adjusting the amount of a liquid in the cell culture vessel, wherein both components for the cell culture solution in the cell culture vessel and components for the composition-adjusted solution in the composition-adjusted solution storage vessel can be controlled continuously through the culture solution composition adjustment means and the amount of the cell culture solution in the cell culture vessel can be adjusted substantially at a constant level.
C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
83.
Measuring unit to be attached to cell culture container, cell culture container, and cultivation condition monitoring system
A measuring unit which is to be attached to a cell culture container configured to accommodate cells to be cultured and a culture solution, includes: a measurer which is configured to measure information related to the cells and the culture solution, in a non-contact manner; and a sensor which is configured to detect at least one of a position, a posture, an impact, an orientation, and vibration.
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
84.
Method and apparatus for measuring liquid level of cell culture solution
A method of measuring a liquid level of a cell culture solution stored in a cell vessel, includes: irradiating the cell culture solution with at least two kinds of light beams including a first light beam having a first wavelength and a second light beam having a second wavelength; measuring a first absorbance of the cell culture solution with respect to the first light beam, and a second absorbance of the cell culture solution with respect to the second light beam; and determining a liquid level of the cell culture solution based on the first absorbance and the second absorbance.
G01F 23/00 - Indication ou mesure du niveau des liquides ou des matériaux solides fluents, p. ex. indication en fonction du volume ou indication au moyen d'un signal d'alarme
A method for producing multilayered cell sheets, including producing a vascular bed which includes an artery-vein loop and in which a capillary vascular network is constructed; layering cell sheets on the vascular bed; and perfusing a culture medium in vitro to construct a vascular network in the cell sheets. The production method enables vascular networks to be constructed in cell sheets and enables thick multilayered cell sheets to foe easily produced by layering the cell sheets. Such thick multilayered cell sheets are useful as in vivo tissue-like products for regenerative medicine for various tissues and for evaluation of drugs and the like.
A61K 35/36 - PeauSystème pileuxOnglesGlandes sébacéesCérumenÉpidermeCellules épithélialesKératinocytesCellules de LangerhansCellules ectodermiques
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A method for manufacturing a multilayered cell sheet characterized in fabricating a vascular bed that constructs a vascular network extending to the surface from a channel for perfusing a medium, the channel being embedded in a gel; and layering a cell sheet onto the vascular bed to construct a vascular network in the cell sheet. This manufacturing method makes it possible to construct a vascular network in the cell sheet and to fabricate a thick multilayered cell sheet in a simple manner by layering cell sheets. Such a thick multilayered cell sheet is useful as an in-vivo tissue substitute in regenerative medicine involving a variety of tissues.
As a result of using a cell culture substrate having a photopolymerization initiator fixed on the surface thereof and having linear polymers fixed on either part or all of the surface by means of the initiator, said photopolymerization initiator being thioxanthone, individual or multiple cells can be efficiently cultured on a specific region of the cell culture substrate, and can be efficiently detached by merely altering the temperature of the substrate surface.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
The purpose of the present invention is to provide a primer for amplifying a telomere sequence. The present invention provides a primer represented by formula (1) or formula (2), and for use in the amplification of a telomere sequence. (1) L1-(R1)n1. In the formula: the repeating units R1 represent a base sequence represented by GTAGGG; n1 represents 5 or 6; when n1 represents 5, L1 is a linker comprising 16 or fewer bases; and when n1 represents 6, L1 is a linker comprising 8 or fewer bases. (2) L2-(R2)n2(X). In the formula: the repeating units R2 represent a base sequence represented by GTAGGG; X represents a sequence obtained by removing or substituting one or two bases in the base sequence represented by GTAGGG; n2 represents 5 or 6; when n2 represents 5, L2 is a linker comprising 4-8 bases; and when n2 represents 6, L2 is a linker comprising 8 bases.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
89.
MATRIX FOR RECOVERING CELL FRAGMENTS FOR THERAPEUTIC USE AND METHOD FOR PRODUCING CELL FRAGMENTS FOR THERAPEUTIC USE USING SAME, AND MATRIX FOR RECOVERING CELL FRAGMENTS FOR SUBCULTURE AND METHOD FOR PRODUCING CELL FRAGMENTS FOR SUBCULTURE USING SAME
The main purpose of the present invention is to provide a matrix for recovering cell fragments for therapeutic use whereby cell fragments capable of exerting a therapeutic effect at a high reproducibility can be obtained. The matrix for recovering cell fragments for therapeutic use, which comprises a stimulus-responsive area showing a change in cell adhesiveness due to a stimulus and a cell non-adhesive area having cell non-adhesiveness, characterized in that the circumference of the stimulus-responsive area is surrounded by the cell non-adhesive area. The above-said purpose can be achieved by providing this matrix.
In order to provide a method for supporting surgery and a treatment support system with which it is possible to visualize remaining treatment regions in a high intensity focused ultrasound (HIFU) therapy, a treatment support system (10) is provided with: an ultrasonic probe (37) that performs a HIFU therapeutic treatment on a subject; an MRI device (1); an ultrasonic diagnostic therapy apparatus (40) that is positioned within the MRI device (1) and enables capturing ultrasonic images of the subject (24); and a three-dimensional position detecting device that detects the position of the ultrasonic probe (37). After treatment, remaining treatment regions are displayed by subtracting the plurality of images obtained by the MRI imaging before and after contrast radiography.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
91.
SYNTHESIS AND ANALYSIS OF NOVEL COMPOUND CAPABLE OF INDUCING DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELL INTO HEPATOCYTE
NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (Japon)
Tokyo Women's Medical University (Japon)
Inventeur(s)
Shiota, Goshi
Hoshikawa, Yoshiko
Matsumoto, Noriko
Matsumi, Yoshiaki
Morimoto, Minoru
Tonoi, Takayuki
Saimoto, Hiroyuki
Ohashi, Kazuo
Okano, Teruo
Abrégé
The purpose is to select a low-molecular-weight compound which is effective for inducing the differentiation of a mesenchymal stem cell into a hepatocyte and develop a differentiation-inducing method which has excellent efficiency of inducing a mesenchymal stem cell into a hepatocyte and is safe. At least one compound selected from compounds represented by formula (1) and formula (2), a salt of the compound, or a solvate of the compound or the salt; a differentiation-inducing agent comprising at least one compound selected from compounds represented by formula (1) and formula (2), a salt of the compound, or a solvate of the compound or the salt; and a differentiation-inducing agent comprising a compound represented by formula (8), a salt of the compound or a solvate of the compound or the salt.
C07C 251/86 - Hydrazones ayant des atomes de carbone, liés par des liaisons doubles, de groupes hydrazone liés à des atomes de carbone de cycles aromatiques à six chaînons
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
C07C 43/225 - Éthers une liaison sur l'oxygène de la fonction éther étant sur un atome de carbone d'un cycle aromatique à six chaînons contenant des atomes d'halogène
C07D 307/52 - Radicaux substitués par des atomes d'azote ne faisant par partie d'un radical nitro
The present invention provides a method for producing a cardiomyocyte sheet using a group of cells derived from embryonic stem cells. The method is characterized by mixing Flk/KDR-positive cells, cardiomyocytes, endothelial cells and parietal cells all derived from embryonic stem cells and culturing the mixed cells. The cardiomyocyte sheet is so adapted as to release a VEGF therefrom, and therefore can be used as a therapeutic agent for heart diseases.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
A cell culture apparatus includes: an isolator in which a sterile space accommodating a cell incubator filled with a culture solution containing cells to be cultured is disposed; a sampling unit configured to sample the culture solution in the cell incubator; a delivery flow path through which an inside of the sterile space and an outside of the sterile space communicate with each other, the delivery flow path configured to limit a flow in the delivery flow path to a direction that is directed from the inside of the sterile space toward the outside of the sterile space; and a culture solution delivering section configured to deliver the sampled culture solution to the outside of the sterile space via the delivery flow path.
A pH measuring method includes: illuminating a medium solution, which includes: a first material; and a second material, with a plurality of light beams, which includes: a first light beam, a wavelength of which corresponds to a first absorption peak; a second light beam, a wavelength of which corresponds to a second absorption peak or a second convergence point; a third light beam, a wavelength of which corresponds to a third absorption peak or a third convergence point; and a fourth light beam, a wavelength of the fourth light beam at which an absorbance of at least one of the first and second materials is converged irrespective of a pH; receiving transmitted or reflected light beams of the first to fourth light beams; measuring absorbances at the wavelengths of the received light beams respectively; and calculating a pH of the medium solution based on the absorbances.
G01N 21/31 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique
G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
An atom transfer radical polymerization initiator is immobilized on the surface of a monolithic porous body, and a polymer of which the hydration force can vary at temperatures ranging from 0 to 80˚C is grown from the initiator in the presence of a catalyst by an atom transfer radical method. In this manner, it becomes possible to produce a temperature-responsive monolithic porous body having, immobilized on the surface thereof at a high density, a polymer of which the hydration force can vary at temperatures ranging from 0 to 80˚C.
The production of an angiogenesis-promoting cytokine can be optimized and the formation of a vascular endothelial network can be optimized by altering the kinds of cells constituting a layered cell sheet, the mixing ratio thereof and the number of the disseminated cells to thereby change the conditions of the cells in the layered cell sheet.
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
C12M 3/04 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des couches minces
A method of measuring a pH of a solution includes: emitting light beams of two wavelengths from one side of a measuring region of a solution into which an indicator is mixed, while pulsating the solution in the measuring region; receiving at least one of transmitted light beams and reflected light beams of the emitted light beams on the other side of the measuring region, while pulsating the solution in the measuring region; obtaining absorbances of the two wavelengths based on the received at least one of the transmitted light beams and the reflected light beams; obtaining an absorbance ratio from the obtained absorbances; and calculating a pH value of the solution based on the obtained absorbance ratio and an absorbance ratio/pH value correspondence database which is previously stored.
G01N 21/31 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
98.
CELL CULTURE TREATMENT SYSTEM, AND METHOD FOR CONNECTION OF MODULES FOR CELL CULTURE TREATMENT SYSTEM
Provided is a cell culture treatment system for performing a culture treatment of cells or tissues in the fields of regenerative medicine and the like, whereby it becomes possible to keep the sterility of the system by preventing the invasion of viruses, human-derived cells other than those to be subjected to the culture treatment and the like from the outside of the system into the inside of closed spaces, and it also becomes possible to perform a cell culture treatment by combining multiple culture treatment modules by connecting or removing the multiple modules selectively in accordance with a wide variety of cell culture treatment processes while keeping the hermeticity of the closed spaces of the modules.
[Problem] To provide a biomarker for the diagnosis of fatty liver diseases. [Solution] One or more compounds selected from the group consisting of etiocholanolone 3-sulfate, nervonic acid, α-tocopherol, 16-hydroxydehydroepiandrosterone 3-sulfate, dehydroepiandrosterone 2-sulfate, taurine, 15-hydroxyeicosatetraenoic acid, serotonin and thyroxine are used as biomarkers for the diagnosis, and fatty liver diseases are diagnosed by measuring the amounts of the compounds contained in a blood sample taken.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'ionisation des gaz, p. ex. des aérosolsRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p. ex. l'émission cathodique
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
100.
INHIBITOR OF OSTEOCLAST FORMATION CONTAINING ANTI-VDAC ANTIBODY
The present invention provides a therapeutic agent or a preventative agent containing anti-VDAC antibody for diseases in which there is increased activation of osteoclasts, such as rheumatoid arthritis, and an inhibitor of human osteoclast formation containing anti-VDAC antibody.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
brevets
